Alopecia Areata
An Introduction to Alopecia areata
Alopecia areata (AA) is an inflammatory cause of unpredictable, patchy hair loss that affects up to 2% of the population. Current treatment options for AA involve local steroid injections at the site of alopecia combined with topical retinoids; however, these are of limited efficacy and are associated with significant adverse effects. Recent insights into the pathogenesis of AA have allowed the development of novel treatment options, in particular, Janus kinase (JAK) inhibitors and cytokine-targeted therapy. There have also been reports of hair regrowth following treatment with platelet-rich plasma, stem cell-based therapy approaches and faecal microbiota transplantation.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
The BRAVE-AA-PEDS study focused on 257 adolescents with severe alopecia areata, investigating the efficacy of baricitinib. The trial demonstrated promising results with 42% achieving significant improvement by week 36, and reassuring safety data.
Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.
Explore some of the key insights from EADV 2023: Prof. Thierry Passeron illuminates pigmentary disorders breakthroughs, Dr Raj Chovatiya unveils atopic dermatitis innovations, Prof. Leonardo Marini sheds light on aesthetic medicine developments, and Prof. Dedee Murrell reveals treatment progress exciting clinical trials and key discoveries in blistering and autoimmune diseases. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.Â
Janus kinase inhibitors (JAKis) have transformed the landscape of dermatological therapy over the last 2 years, with six United States Food and Drug Administration approvals and further clinical trials in progress.1 JAKis have proven highly efficacious in dermatological diseases, by blocking ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
